glizide is a sulfonylurea-based hypoglycemic drug. It plays a hypoglycemic effect by promoting the secretion of insulin . It has a significant hypoglycemic effect. Due to the adverse reactions of this type of drug to hypoglycemic and weight-enhancing, this type of drug is limited in clinical use. Moreover, with the emergence of new oral hypoglycemic drug DPP-4 inhibitors such as linagliptin, and SGLT2 inhibitors such as dapagliflozin, , the clinical status of sulfonylurea-based hypoglycemic drug has gradually declined. It has now become a second-tier oral hypoglycemic drug
Despite this, for patients who are intolerant of the first-line drug metformin or have contraindications to metformin, sulfonylurea-based drugs are still an important alternative variety. When the effect of using metformin alone is not good, sulfonylurea-based drugs are also an important combination drug variety.
glizid and glizid sustained release tablets, as important members of the sulfonylurea family, have the following differences in clinical application
1. The duration of hypoglycemic effects is different. As a sustained release preparation, glizid sustained release tablets have a longer action time than short-acting gliquine tablets. Gliquine tablets need to be taken 3 times a day, while glizid sustained release tablets only need to be taken once a day.
2 Applicable populations
For patients with pre-practice high blood, they can choose gliquinolon tablets, 2-3 times a day, and take medication before meals. For patients with 2 diabetes who mainly have high fasting blood sugar, they can choose glizit sustained release tablets, and they can take them once a day. Patients with high blood sugar in after fasting and are more suitable for choosing long-acting preparations such as glizide sustained release tablets. However, for patients with renal insufficiency, gliquiquine has a unique advantage. Only 5% of gliquiquine are excreted by the kidneys, and can still be used in patients with glomerular filtration rate (eGFR) of 30%.
3
33
3clinical status
glizit is the only sulfonylurea drug listed in the 2017 WHO 20th edition basic drug list recommended to the world.
Four adverse reactions are different. Compared with short-acting sulfonylureas such as gliquinole, there is more clinical evidence that the incidence of adverse reactions of hypoglycemia and weight gain is low, and the cardiovascular safety is better.
